Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 11.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | tive Agreement. The information set forth under Item 5.02 of this Current Report on Form 8-K is incorporated herein by r |
Stammdaten
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Unternehmen & Branche
| Name | Zymeworks Inc. |
|---|---|
| Ticker | ZYME |
| CIK | 0001937653 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,05 Mrd. USD |
| Beta | 1,20 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 105,965,000 | -81,130,000 | -1.08 | 346,527,000 | 268,501,000 |
| 2025-09-30 | 10-Q | 27,614,000 | -19,602,000 | -0.26 | 397,269,000 | 320,064,000 |
| 2025-06-30 | 10-Q | 48,726,000 | 2,317,000 | 0.03 | 408,385,000 | 334,506,000 |
| 2025-03-31 | 10-Q | 27,110,000 | -22,636,000 | -0.30 | 425,522,000 | 324,967,000 |
| 2024-12-31 | 10-K | 76,304,000 | -122,695,000 | -1.62 | 463,091,000 | 338,768,000 |
| 2024-09-30 | 10-Q | 16,000,000 | -29,850,000 | -0.39 | 487,152,000 | 366,978,000 |
| 2024-06-30 | 10-Q | 19,243,000 | -37,686,000 | -0.49 | 515,634,000 | 406,161,000 |
| 2024-03-31 | 10-Q | 10,030,000 | -31,653,000 | -0.42 | 553,752,000 | 437,999,000 |
| 2023-12-31 | 10-K | 76,012,000 | -118,674,000 | -1.72 | 580,880,000 | 464,806,000 |
| 2023-09-30 | 10-Q | 16,506,000 | -28,687,000 | -0.41 | 556,366,000 | 424,344,000 |
| 2023-06-30 | 10-Q | 7,002,000 | -51,152,000 | -0.76 | 602,054,000 | 448,919,000 |
| 2023-03-31 | 10-Q | 35,578,000 | -24,353,000 | -0.37 | 600,743,000 | 473,538,000 |
| 2022-12-31 | 10-K | 412,482,000 | 124,341,000 | 1.90 | 648,725,000 | 492,956,000 |
| 2022-09-30 | 10-Q | 2,631,000 | -47,846,000 | -0.72 | 300,263,000 | 179,758,000 |
| 2022-06-30 | 10-Q | 5,442,000 | -64,619,000 | -0.97 | 222,282,000 | |
| 2022-03-31 | 10-Q | 1,916,000 | -72,625,000 | -1.19 | 282,444,000 | |
| 2021-12-31 | 10-K | 26,680,000 | -211,843,000 | -4.61 | 389,132,000 | 249,094,000 |
| 2021-09-30 | 10-Q | 4,395,000 | -60,579,000 | -1.25 | 278,929,000 | |
| 2021-06-30 | 10-Q | -67,522,000 | 321,472,000 | |||
| 2021-03-31 | 10-Q | -44,590,000 | 377,145,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.